D58.8 Other specified hereditary hemolytic anemias

Name of the Condition

• Other specified hereditary hemolytic anemias

Summary

Other specified hereditary hemolytic anemias are a group of inherited disorders characterized by the premature destruction of red blood cells (hemolysis), leading to anemia. These conditions result from genetic defects affecting red blood cell structure, function, or metabolism, causing cells to break down faster than they can be replaced. The severity and specific manifestations vary depending on the underlying genetic mutation.

Causes

These anemias are caused by inherited genetic mutations that disrupt normal red blood cell production or stability. Common mechanisms include defects in hemoglobin structure (e.g., unstable hemoglobins), enzyme deficiencies (e.g., pyruvate kinase deficiency), or abnormalities in red blood cell membrane proteins. The mutations are typically autosomal dominant or recessive and may be specific to certain ethnic groups.

Risk Factors

• Family history of hereditary hemolytic anemia
• Inherited genetic mutations (e.g., in genes encoding hemoglobin, enzymes, or membrane proteins)
• Ethnic background (some variants are more prevalent in specific populations)
• Exposure to triggers that exacerbate hemolysis (e.g., infections, certain medications, oxidative stress)

Symptoms

• Fatigue and weakness due to anemia
• Jaundice (yellowing of skin or eyes) from increased bilirubin
• Dark urine (hemoglobinuria)
• Enlarged spleen (splenomegaly)
• Shortness of breath
• Pale skin or mucous membranes
• Rapid heart rate (tachycardia)

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and genetic testing. Blood tests may show anemia, elevated bilirubin, and reticulocytosis (increased immature red blood cells). A peripheral blood smear can reveal abnormal red blood cell shapes or inclusions. Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) may identify abnormal hemoglobin variants. Enzyme assays (e.g., for pyruvate kinase) or membrane protein analysis can confirm specific defects. Genetic testing is often used to identify the underlying mutation and confirm hereditary causes.

Treatment Options

Treatment focuses on managing symptoms and preventing complications. Mild cases may require no specific therapy beyond monitoring. For moderate to severe anemia, blood transfusions may be necessary. Folic acid supplementation supports red blood cell production. In some cases, splenectomy (surgical removal of the spleen) reduces hemolysis but carries risks. Avoiding triggers like certain medications or infections is critical. Emerging therapies, such as gene therapy, are under investigation for specific genetic defects.

Prognosis and Follow-Up

Prognosis varies widely depending on the specific condition and severity. Mild forms may have minimal impact on daily life, while severe cases can lead to chronic anemia and organ damage. Regular follow-up with a hematologist is essential to monitor blood counts, manage complications, and adjust treatment. Lifelong monitoring may be required, especially for those with severe disease or post-splenectomy.

Complications

• Severe anemia requiring frequent transfusions
• Gallstones (from chronic hemolysis)
• Enlarged spleen with potential rupture risk
• Iron overload from repeated transfusions
• Pulmonary hypertension
• Developmental delays in children (in severe cases)

Lifestyle & Prevention

• Avoid known triggers (e.g., certain drugs, infections)
• Maintain a balanced diet rich in iron and folic acid
• Stay hydrated to support red blood cell function
• Engage in regular, moderate exercise as tolerated
• Seek prompt medical care for infections or illness
• Genetic counseling for family planning

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Sudden worsening of fatigue or weakness
• Severe jaundice or dark urine
• Shortness of breath or chest pain
• Signs of infection (fever, chills)
• Abdominal pain (possible splenic enlargement or rupture)

Tips for Medical Coders

Document the specific hereditary hemolytic anemia type (e.g., unstable hemoglobin, enzyme deficiency) to support accurate coding. Include details on genetic testing results, family history, and clinical manifestations. Ensure documentation aligns with the ICD-10-CM code D58.8, which is used for other specified hereditary hemolytic anemias not classified elsewhere. Verify that the diagnosis is confirmed by laboratory or genetic evidence to meet coding guidelines.